Vivo Capital is a reputable and globally recognized healthcare-focused investment firm that has been operating for over 25 years. With approximately $5. 4 billion in assets under management, Vivo Capital offers a range of investment services and products to both private and public healthcare companies.

Their investment strategy involves making strategic investments from their funds, including the $1. 4 billion Vivo Capital Fund IX, which is dedicated to promising private healthcare companies, and the $635 million Vivo Opportunity Fund, focused on promising public healthcare companies. Vivo Capital's private equity investments predominantly support growth capital and product-driven companies involved in the development and commercialization of therapeutics, such as pharmaceuticals, biotechnology, and medical devices.

These investments aid in revenue acceleration and product development to drive value creation. In addition, Vivo Capital's public equity arm, the Vivo Opportunity Fund, primarily invests in small and mid-cap biotechnology, pharmaceutical, healthcare, and life science companies globally. Overall, Vivo Capital's comprehensive investment approach and extensive experience make them a trusted partner for healthcare companies seeking capital infusion and strategic guidance in optimizing growth opportunities in the industry